REDMOND, WA, August 29, 2022 — Pattern Computer®, Inc. (PCI) is pleased to announce the advancement of three additional combination therapy candidates against High-grade Serous Ovarian cancer beyond the first stage of in vitro studies. In all three cases, the drugs showed combined synergy against targeted cancer cells.

These results, added to the company’s prior announcement, bring the total portfolio of synergistic candidates to five. This means that 5 of the firm’s 31 combination therapy candidates in this series of tests (against three different cell lines) have demonstrated synergistic behavior against this cancer. This means that 16.1% of the new drug candidates discovered by Pattern’s Discovery Engine have now moved forward after testing.

These tests were performed at a nationally recognized clinical testing organization.

PCI’s drug discovery efforts are currently focused on oncological malignancies. Using our innovative Pattern Discovery Engine™ (PDE), we have already identified and have under preclinical development, two sets of potential combination therapies for triple-negative Breast Cancer (TNBC), the most difficult to treat and most aggressive subtype of breast cancer. Our capability for discovering polythetic patterns of interacting genes in genomics data is only made possible by the PDE. In addition, we are actively and aggressively applying this to other complex and intractable cancers including Colorectal Cancer, Lung Cancer, and metastatic Castration-Resistant Prostate Cancer (mCRPC).

“We are excited to be able to announce that we now have increased our portfolio of Ovarian Cancer drug candidates by three, bringing the total count of combination drugs showing synergy against this disease to a total of five. At the same time, this now brings our total number of pipelines of new drugs showing efficacy against the top five global cancer killers to seven. We feel that this third round of current outcomes go a long way toward providing solid evidence that our Pattern Discovery Engines are capable of rapid and accurate drug discovery using mathematics and techniques which are demonstrably more effective than those used previously,” said Mark Anderson, Chair and CEO, Pattern Computer.

“We can also now announce that, for this calendar year on average Pattern is creating five new novel combination drugs per month against the top five cancer killers. Perhaps more importantly, Pattern is creating one of these per month which are passing tests for effectiveness against live cancer cells – one new cancer drug candidate per month for the top five cancers.”

“And, as part of our larger StarBright Project, this announcement represents moving forward in just two of the five cancer killers we are working on today. We will be making additional announcements shortly on new discoveries in metastatic Castration-Resistant Prostate Cancer (mCRPC), Lung Cancer and Colorectal Cancer. Our whole team is very excited and proud regarding the speed and accuracy to date of these very early steps. As an example, we were able to identify new genetic discoveries in the computational phase of the Ovarian cancer work in just six weeks.

“By making a positive difference in TPN Breast Cancer, Serous Ovarian Cancer, Lung Cancer, Colorectal Cancer, and Metastatic Castration-Resistant Prostate Cancer, we hope to show that this new Pattern Discovery Engine approach to medicine will indeed be disruptive, both in making major steps forward in oncology and other fields, and in moving far beyond the results of yesterday’s mathematical tools,” Anderson added.

About Pattern Computer

Pattern Computer uses its proprietary Pattern Discovery Engine™ to solve the most important and most intractable problems in business and medicine. Its proprietary mathematical techniques can find complex patterns in very-high-order data that have eluded detection by other, much larger systems.

While the company is currently applying its computational platform to the challenging fields of drug discovery and treatments for the top five killer cancers, it is also making pattern discoveries for partners in several other sectors, including additional biomedical research, materials science, aerospace manufacturing, veterinary medicine, air traffic operations, and finance. PCI has just announced the world’s first Explainable AI (XAI) for neural networks and is the proud inventor of the ProSpectral™ device, the world’s most advanced Covid detection system.

CONTACT: Brad Holtz – 301.529.9944 – bh@patterncomputer.com

The foregoing contains statements about Pattern Computer’s future that are not statements of historical fact. These statements are “forward-looking statements” for purposes of applicable securities laws and are based on current information and/or management’s good-faith belief as to future events. The words “believe,” “expect,” “anticipate,” “project,” “should,” “could,” “will,” and similar expressions signify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance. By their nature, forward-looking statements involve inherent risk and uncertainties, which change over time, and actual performance could differ materially from that anticipated by any forward-looking statements. Pattern Computer undertakes no obligation to update or revise any forward-looking statement.

Copyright © 2022 Pattern Computer Inc. All Rights Reserved. Pattern Computer, Inc., Pattern Discovery Engine, Dimensional Navigator, and ProSpectral are trademarks of Pattern Computer, Inc. or its subsidiaries. Other trademarks may be trademarks of their respective owners.